Natco Pharma Ltd.

Natco Pharma is currently trading at Rs. 1417.20, up by 47.10 points or 3.44 % from its previous closing of Rs. 1370.10 on the BSE.

The scrip opened at Rs. 1370.75 and has touched a high and low of Rs. 1428.00 and Rs. 1357.95 respectively. So far 9085 shares were traded on the counter.

The BSE group 'B' stock of face value Rs. 10 has touched a 52 week high of Rs. 1406.00 on 04-Sep-2014 and a 52 week low of Rs. 585.00 on 13-Sep-2013.

Last one week high and low of the scrip stood at Rs. 1406.00 and Rs. 1233.00 respectively. The current market cap of the company is Rs. 4670.08 crore.

The promoters holding in the company stood at 53.52 % while Institutions and Non-Institutions held 23.30 % and 23.18 % respectively.

Natco Pharma’s marketing partner in the USA, Breckenridge Pharmaceutical, Inc. (BPI), has filed an Abbreviated New Drug Application (ANDA) for Everolimus 0.25mg, 0.5mg, and 0.75mg Tablets. Both the entities’ Paragraph IV ANDA was filed on the First-to-File date and expected to be the only generic that is entitled to the 180-day exclusivity period.

Novartis AG sells Everolimus 0.25mg, 0.5mg, and 0.75mg Tablets under Brand name Zortress in the USA market. Zortress is used to prevent organ rejection after a kidney or liver transplant. Zortress generated sales of $43.5 million for the twelve-month period ending July 2014, based on industry sales data.

Natco Pharma was promoted as a private company to be in the business of research, developing, manufacturing and marketing of pharmaceutical substances and finished dosage forms for Indian and International markets.